Aes-103 5-hydroxymethyl-2-furfural: Phase I/IIa started

AesRx began a double-blind, placebo-controlled, U.S. Phase I/IIa trial to evaluate single ascending-doses of oral Aes-103 in 18 patients with stable sickle cell disease. Aes-103 has Orphan Drug design...